Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared on LinkedIn:
“A milestone moment in bladder cancer care
Today, we announced that the U.S. FDA has granted Priority Review to our VOLGA regimen, a perioperative immunotherapy combination for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for, or have declined, cisplatin-based chemotherapy.
Why This Matters
Even after bladder removal surgery, patients with MIBC continue to face a significant risk of disease recurrence. They need options that can meaningfully change that trajectory.
What the Science Shows
The Phase III VOLGA trial delivered positive high-level results, demonstrating improvements in both event-free survival and overall survival – two critical outcomes for patients and their families.
The Bigger Picture
VOLGA is our third positive readout in bladder cancer in just 18 months, joining NIAGARA and POTOMAC. These advances are redefining what’s possible in bladder cancer and moving us closer to our larger ambition of one day eliminating cancer as a cause of death.
Thank you to every patient, caregiver, investigator, and AstraZeneca colleague who made this possible.
Full VOLGA data will be presented at an upcoming medical meeting. Stay tuned.”
Read the Full Announcement
Other articles featuring Mohit Manrao on OncoDaily.